Influence of formulation on jet nebulisation quality of α1 protease inhibitor

M. P. Flament, P. Leterme, T. Burnouf, A. Gayot

研究成果: 雜誌貢獻文章

8 引文 (Scopus)

摘要

As foam appears during solution constitution and nebulisation of α1 protease inhibitor (α1 PI), we selected in a previous work, antifoams likely to be associated with an α1 PI solution to be nebulised: span 65 at a 0.025% concentration and cetyl alcohol at a 0.05% concentration associated with tyloxapol at 0.025% concentration. The purpose of this study was, on the one hand to study the influence of the formulation on nebulisation quality by relating physicochemical properties and nebulisation capacity, and on the other hand, to define the α1 PI that will be retained for a clinical study. The properties of the different α1 PI formulations are compared: surface tension, viscosity, time required to constitute the protein solution and pH. Nebulisation quality is evaluated under different operating conditions by measuring the droplet size, the quantity of α1 PI nebulised, nebulisation time and the quantity of α1 PI likely to reach the lungs which was subjected to statistical analysis. The statistical analysis of results indicates that the addition of the cetyl alcohol/tyloxapol mixture improves nebulisation effectiveness by significantly increasing the quantity of drug nebulised and therefore the quantity of α1 PI likely to reach the lungs. It is this formulation that will be retained for clinical trials. We check that the nebuliser and operating conditions influence all the parameters, that is to say the respirable fraction, the quantity nebulised and the nebulisation time. Although there is no interaction between the nebuliser and the formulation, nebulisation quality is the combined result of the formulation, the nebuliser and the operating conditions. Copyright (C) 1999 Elsevier Science Ireland Ltd.
原文英語
頁(從 - 到)101-109
頁數9
期刊International Journal of Pharmaceutics
178
發行號1
DOIs
出版狀態已發佈 - 二月 1 1999
對外發佈Yes

指紋

Protease Inhibitors
Nebulizers and Vaporizers
Lung
Surface Tension
Constitution and Bylaws
Viscosity
Clinical Trials
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Pharmaceutical Science

引用此文

Influence of formulation on jet nebulisation quality of α1 protease inhibitor. / Flament, M. P.; Leterme, P.; Burnouf, T.; Gayot, A.

於: International Journal of Pharmaceutics, 卷 178, 編號 1, 01.02.1999, p. 101-109.

研究成果: 雜誌貢獻文章

Flament, M. P. ; Leterme, P. ; Burnouf, T. ; Gayot, A. / Influence of formulation on jet nebulisation quality of α1 protease inhibitor. 於: International Journal of Pharmaceutics. 1999 ; 卷 178, 編號 1. 頁 101-109.
@article{936c3e6570f64501931f1fcf31cc6dd7,
title = "Influence of formulation on jet nebulisation quality of α1 protease inhibitor",
abstract = "As foam appears during solution constitution and nebulisation of α1 protease inhibitor (α1 PI), we selected in a previous work, antifoams likely to be associated with an α1 PI solution to be nebulised: span 65 at a 0.025{\%} concentration and cetyl alcohol at a 0.05{\%} concentration associated with tyloxapol at 0.025{\%} concentration. The purpose of this study was, on the one hand to study the influence of the formulation on nebulisation quality by relating physicochemical properties and nebulisation capacity, and on the other hand, to define the α1 PI that will be retained for a clinical study. The properties of the different α1 PI formulations are compared: surface tension, viscosity, time required to constitute the protein solution and pH. Nebulisation quality is evaluated under different operating conditions by measuring the droplet size, the quantity of α1 PI nebulised, nebulisation time and the quantity of α1 PI likely to reach the lungs which was subjected to statistical analysis. The statistical analysis of results indicates that the addition of the cetyl alcohol/tyloxapol mixture improves nebulisation effectiveness by significantly increasing the quantity of drug nebulised and therefore the quantity of α1 PI likely to reach the lungs. It is this formulation that will be retained for clinical trials. We check that the nebuliser and operating conditions influence all the parameters, that is to say the respirable fraction, the quantity nebulised and the nebulisation time. Although there is no interaction between the nebuliser and the formulation, nebulisation quality is the combined result of the formulation, the nebuliser and the operating conditions. Copyright (C) 1999 Elsevier Science Ireland Ltd.",
keywords = "α Protease inhibitor, Antifoam, Formulation, Nebulisation quality, Surface tension",
author = "Flament, {M. P.} and P. Leterme and T. Burnouf and A. Gayot",
year = "1999",
month = "2",
day = "1",
doi = "10.1016/S0378-5173(98)00354-8",
language = "English",
volume = "178",
pages = "101--109",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Influence of formulation on jet nebulisation quality of α1 protease inhibitor

AU - Flament, M. P.

AU - Leterme, P.

AU - Burnouf, T.

AU - Gayot, A.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - As foam appears during solution constitution and nebulisation of α1 protease inhibitor (α1 PI), we selected in a previous work, antifoams likely to be associated with an α1 PI solution to be nebulised: span 65 at a 0.025% concentration and cetyl alcohol at a 0.05% concentration associated with tyloxapol at 0.025% concentration. The purpose of this study was, on the one hand to study the influence of the formulation on nebulisation quality by relating physicochemical properties and nebulisation capacity, and on the other hand, to define the α1 PI that will be retained for a clinical study. The properties of the different α1 PI formulations are compared: surface tension, viscosity, time required to constitute the protein solution and pH. Nebulisation quality is evaluated under different operating conditions by measuring the droplet size, the quantity of α1 PI nebulised, nebulisation time and the quantity of α1 PI likely to reach the lungs which was subjected to statistical analysis. The statistical analysis of results indicates that the addition of the cetyl alcohol/tyloxapol mixture improves nebulisation effectiveness by significantly increasing the quantity of drug nebulised and therefore the quantity of α1 PI likely to reach the lungs. It is this formulation that will be retained for clinical trials. We check that the nebuliser and operating conditions influence all the parameters, that is to say the respirable fraction, the quantity nebulised and the nebulisation time. Although there is no interaction between the nebuliser and the formulation, nebulisation quality is the combined result of the formulation, the nebuliser and the operating conditions. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - As foam appears during solution constitution and nebulisation of α1 protease inhibitor (α1 PI), we selected in a previous work, antifoams likely to be associated with an α1 PI solution to be nebulised: span 65 at a 0.025% concentration and cetyl alcohol at a 0.05% concentration associated with tyloxapol at 0.025% concentration. The purpose of this study was, on the one hand to study the influence of the formulation on nebulisation quality by relating physicochemical properties and nebulisation capacity, and on the other hand, to define the α1 PI that will be retained for a clinical study. The properties of the different α1 PI formulations are compared: surface tension, viscosity, time required to constitute the protein solution and pH. Nebulisation quality is evaluated under different operating conditions by measuring the droplet size, the quantity of α1 PI nebulised, nebulisation time and the quantity of α1 PI likely to reach the lungs which was subjected to statistical analysis. The statistical analysis of results indicates that the addition of the cetyl alcohol/tyloxapol mixture improves nebulisation effectiveness by significantly increasing the quantity of drug nebulised and therefore the quantity of α1 PI likely to reach the lungs. It is this formulation that will be retained for clinical trials. We check that the nebuliser and operating conditions influence all the parameters, that is to say the respirable fraction, the quantity nebulised and the nebulisation time. Although there is no interaction between the nebuliser and the formulation, nebulisation quality is the combined result of the formulation, the nebuliser and the operating conditions. Copyright (C) 1999 Elsevier Science Ireland Ltd.

KW - α Protease inhibitor

KW - Antifoam

KW - Formulation

KW - Nebulisation quality

KW - Surface tension

UR - http://www.scopus.com/inward/record.url?scp=0033044720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033044720&partnerID=8YFLogxK

U2 - 10.1016/S0378-5173(98)00354-8

DO - 10.1016/S0378-5173(98)00354-8

M3 - Article

C2 - 10205630

AN - SCOPUS:0033044720

VL - 178

SP - 101

EP - 109

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

ER -